SSTR2 and neoplasm: Lead specific chelator-PEG2-[Tyr3,Thr8]-octreotide (PSC-PEG2-TOC) (VMT-α-NET) is a somatostatin subtype 2 (SST2) receptor targeting peptide for the treatment of neuroendocrine tumors (NETs) that exhibits rapid tumor accumulation, high tumor retention, and rapid renal excretion [7].